KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Depreciation & Amortization (CF) (2017 - 2026)

Aquestive Therapeutics has reported Depreciation & Amortization (CF) over the past 9 years, most recently at $130000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 11.56% year-over-year to $130000.0; the TTM value through Dec 2025 reached $548000.0, down 23.68%, while the annual FY2025 figure was $548000.0, 23.68% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $130000.0 at Aquestive Therapeutics, down from $139000.0 in the prior quarter.
  • Over five years, Depreciation & Amortization (CF) peaked at $755000.0 in Q1 2021 and troughed at $130000.0 in Q4 2025.
  • A 5-year average of $398100.0 and a median of $307000.0 in 2023 define the central range for Depreciation & Amortization (CF).
  • Biggest five-year swings in Depreciation & Amortization (CF): rose 17.63% in 2023 and later plummeted 68.52% in 2024.
  • Year by year, Depreciation & Amortization (CF) stood at $731000.0 in 2021, then tumbled by 45.69% to $397000.0 in 2022, then rose by 17.63% to $467000.0 in 2023, then plummeted by 68.52% to $147000.0 in 2024, then decreased by 11.56% to $130000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for AQST at $130000.0 in Q4 2025, $139000.0 in Q3 2025, and $140000.0 in Q2 2025.